Detalhe da pesquisa
1.
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study).
Ann Hematol
; 98(2): 361-367, 2019 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-30353388
2.
Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.
Br J Haematol
; 177(5): 741-750, 2017 06.
Artigo
Inglês
| MEDLINE | ID: mdl-28419408
3.
Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy.
Onco Targets Ther
; 7: 1043-50, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-24966686